Shorts

Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.

0:38

Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer

5 months ago

Karie Danielle Keera Runcie, MD

A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.

1:16

What New Tools Can Improve Mental Health Screening in Cancer Care?

5 months ago

Julian C. Hong, MD, MS

Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.

0:49

Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group

5 months ago

Karie Danielle Keera Runcie, MD

Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.

0:44

Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer

5 months ago

Bradley J. Stish, MD

$Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.$

0:45

Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma

5 months ago

Maria-Victoria Mateos, MD, PhD

Despite accounting for less than 1% of prostate cancer diagnoses, neuroendocrine prostate cancer (NEPC) is associated with suboptimal outcomes in the space, according to Rahul Aggarwal, MD.

0:49

Highlighting an Unmet Need in Neuroendocrine Prostate Cancer

5 months ago

Rahul R. Aggarwal, MD

The phase 3 CHALLENGE trial established a significant survival advantage among patients with colorectal cancer who underwent a structured exercise program, according to Linda Carlson, PhD, RPsych.

1:05

Could Exercise Be Prescribed as a Standard of Care for Cancer Treatment?

5 months ago

Linda E. Carlson, PhD

In a discussion with CancerNetwork®, Guenther Koehne, MD, highlighted the rapid development of therapeutic options in the multiple myeloma field, which has seen an increase in novel immunotherapies and a decrease in the use of chemotherapy.

0:48

Is a Functional Cure Possible in Multiple Myeloma Therapy?

5 months ago

Guenther Koehne, MD

0:30

Care Coordination Experiences in Breast Cancer

5 months ago

Nicole Arrato, PhD

Joaquim Bellmunt, MD, PhD, discussed the emergence of EVP as a standard of care regardless of fitness among all cisplatin-eligible MIBC populations.

1:21

Affirming Enfortumab Vedotin/Pembrolizumab as a Standard Across MIBC Groups

5 months ago

Joaquim Bellmunt, MD, PhD

In a conversation with CancerNetwork®, Nicolaus Kröger, MD, detailed how JAK inhibition can work in tandem with transplantation to improve outcomes among patients with myelofibrosis.

0:35

JAK Inhibitors May Improve Transplantation Outcomes in Myelofibrosis

5 months ago

Nicolaus Kröger, MD

Joy Li, MD, discussed findings from a retrospective analysis of patients treated with enfortumab vedotin with or without pembrolizumab in the adjuvant setting for at least 2 cycles of treatment at the 2026 ASCO GU Symposium.

1:04

Should You Discontinue Therapy for Urothelial Carcinoma During Toxicity?

5 months ago

Joy Li, MD

0:34

Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction

6 months ago

Chiara Acquati, PhD, LMSW, FAOSW

Benjamin Garmezy, MD, discussed safe management practices for treatment-emergent adverse effects (TEAEs) with MRT-2359 plus enzalutamide in the treatment of androgen receptor ligand-binding domain-mutated metastatic castration-resistant prostate cancer.

0:49

Examining Optimal Management Strategies for MRT-2359 in LBD-Mutant CRPC

6 months ago

Benjamin Garmezy, MD

1:07

When Do New Mental Health Disorders Occur Most in Patients with Cancer?

6 months ago

Julian C. Hong, MD, MS

1:03

Chemobrain Vs Dementia: Understanding the Difference

6 months ago

Yesne Alici, MD

In a discussion with CancerNetwork®, Natalia Neparidze, MD, spoke about the importance of minimal residual disease (MRD) as a relevant end point for clinical trials assessing novel therapeutic strategies among patients with multiple myeloma.

0:40

MRD is ‘Exceedingly Helpful’ in Assessing Multiple Myeloma Disease Course

6 months ago

Natalia Neparidze, MD

After the FDA granted priority review to rusfertide as a potential therapeutic option for patients with polycythemia vera, CancerNetwork® spoke with Andrew Kuykendall, MD, about what a potential FDA approval would mean for these patients.

0:45

Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard

6 months ago

Andrew T. Kuykendall, MD

Maha Hussain, MD, MBChB, discussed advantages associated with docetaxel-containing triplet regimens for this patients with metastatic HSPC following a Medical Crossfire session she was a presenter for.

1:22

Triplet Therapy Appears to Be Generally Well Tolerated in Metastatic HSPC

6 months ago

Maha Hussain, MD

Tanya Dorff, MD, discussed findings from her presentation comparing doublet and triplet regimens among patients with hormone-sensitive prostate cancer within a Medical Crossfire session held at the New York GU Cancers Congress.

1:34

Delineating Distinct Advantages With Doublet Therapy in HSPC

6 months ago

Tanya B. Dorff, MD

0:34

Exploring AI Use in Breast Radiation Oncology

6 months ago

Molly Ingersoll, PhD, discussed the background behind an analysis, which assessed biological differences underlying sex- and gender-based disparities in bladder cancer outcomes.

0:40

Highlighting Sex-Based Disparities in Bladder Cancer Outcomes

6 months ago

Molly Ingersoll, PhD

In this GU Gemstone, Tanya Barauskas Dorff, MD, spoke with CancerNetwork at NY GU.

0:39

GU Gemstones: Tanya B. Dorff, MD

6 months ago

Tanya B. Dorff, MD

Sympathetic nerves actively signal to cancer-associated fibroblasts within the pancreatic tumor microenvironment, inducing a state that promotes tumor aggression.

0:57

Denervation Shows Different Pancreatic Tumor Reductions Across Sexes

6 months ago

Sebnem Ece Eksi, PhD

0:43

Is Proton Therapy Clinically Effective in Breast Cancer?

6 months ago

Chirag Shah, MD

0:44

MajesTEC-3 Trial Shows ‘Remarkable’ Outcomes in R/R Multiple Myeloma

6 months ago

Rajshekhar Chakraborty, MD

During a visit to Columbia University Herbert Comprehensive Cancer Center, CancerNetwork® spoke with Nicole Lamanna, MD, about the implications of the phase 3 AMPLIFY trial (NCT03836261) showing improved efficacy with acalabrutinib (Calquence) plus venetoclax (Venclexta) vs standard of care among patients with chronic lymphocytic leukemia (CLL).

0:31

AMPLIFY Trial Affirms Shift Away From Chemoimmunotherapy in CLL

6 months ago

Nicole Lamanna, MD

Sahil Doshi, MD, discussed the potential for dose reduction strategies with ipilimumab and nivolumab for the treatment of patients with advanced clear cell renal cell carcinoma.

1:14

Considering Reduced Dose Immunotherapy for Frail Metastatic ccRCC Groups

6 months ago

Sahil D. Doshi, MD

In a visit to Columbia University Herbert Irving Cancer Research Center, CancerNetwork® spoke with Brian Henick, MD, about potential adverse effects that may arise with the use of prophylactic steroids for patients who undergo immunotherapy for lung cancer and other diseases.

0:53

Addressing Steroid-Related Toxicities During Immunotherapy for Lung Cancer

6 months ago

Brian Henick, MD

In a recent visit to Columbia University Irving Cancer Research Center, expert researchers and clinicians shared insights on critical therapeutic developments across their respective disciplines.

0:50

Key Advances Across Oncology Research and Care at Columbia University

6 months ago

Russ Conroy

Shorts

Trending on CancerNetwork

Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA